Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR1 | P47211 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.35 |
| ▸ | ENO1 | P06733 | 1/20 | 0.34 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 4/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | GPR39 | O43194 | 1/20 | 0.30 |
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5032204 | 0.90 | GALR1 (0.41) | GALR1SOS1ENO1KCNH3IDH1 | |
| SCHEMBL4839723 | 0.89 | GALR1 (0.42) | GALR1SOS1ENO1KCNH3IDH1 | |
| SCHEMBL5033962 | 0.89 | GALR1 (0.41) | GALR1SOS1ENO1KCNH3IDH1 | |
| SCHEMBL4829579 | 0.89 | GALR1 (0.41) | GALR1SOS1ENO1KCNH3IDH1 | |
| SCHEMBL5033742 | 0.89 | GALR1 (0.41) | GALR1SOS1ENO1KCNH3IDH1 | |
| SCHEMBL4836077 | 0.88 | GALR1 (0.40) | GALR1SOS1ENO1KCNH3IDH1 | |
| SCHEMBL4839616 | 0.88 | GALR1 (0.55) | GALR1SOS1ENO1CDK1CDK4 | |
| SCHEMBL4837841 | 0.88 | GALR1 (0.55) | GALR1SOS1ENO1CDK1CDK4 | |
| SCHEMBL6013860 | 0.88 | GALR1 (0.55) | GALR1SOS1ENO1CDK1CDK4 | |
| SCHEMBL5032227 | 0.88 | GALR1 (0.40) | GALR1SOS1ENO1KCNH3IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | GALR1 1159/4885SOS1 762/4885ENO1 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.